SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BSD Medical (Long Term Investment Oriented)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: fwhco who wrote (98)2/1/2013 10:47:57 PM
From: nothingoutofbounds1 Recommendation   of 178
 
It was my understanding that RFA was limited in Standard-OF-Care for HCC to tumors <3 cm. HEAT was comparing "RFA-alone" in tumors from 3cm to 7cm vs. RFA+T-DOX with the same tumor range. That higher range of tumor size meant to me that the trial success was assured if T-Dox performed as expected, and I believe that was a reasonable expectation. - fwhco

Thanks for the reply and I think I understand your point here. I thought T-Dox was more hype than substance, but your explanation is reasonable if a person had any belief that the drug would perform at less than hyped up expectations, it should still be able to outperform RFA.

As to you other point about switching to MWA, I fully agree that if they were successful they would have made the change. Really, my second question is/was WORTHLESS and I should not have included it... especially considering that we all believe BSD equipment is superior and it is obvious that if T-Dox was successful it would have helped BSD on some level.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News